Mathieu Fournier presently serves as Chief Scientific Officer at Neopharm Labs. This challenging role allows him to apply his global knowledge and expertise of analytical chemistry in the pharmaceutical industry to meet the evolving business demands of various customers from the life sciences industry.

Mathieu has over 25 years of experience in applied research & development within the pharmaceutical industry. Over the course of his career, he managed the development & validation of methods to support routine testing, risk assessments and various studies required for NDA/ANDA submissions and post-commercial support. He is also experienced in providing answers to health authorities as a subject matter expert for several types of dosage forms such as tablets & capsules, ophthalmic solutions and injectable products.

Mathieu’s speciality in mass spectrometry brought him to develop lines of analytical services to support technical issues related to elemental impurities, extractables & leachables and genotoxic impurities. In his current role he is expanding his ability for strategic implementation of new services to multiple fields of expertise, such as biopharmaceutical drug product testing.

Mathieu holds a Master of Science degree in Analytical Chemistry, specializing in small molecule analysis by LC/MS from the Université du Québec à Montréal (UQÀM).